Mersana Confirms Clinical Trial Progress on Lead Oncology Program at ASCO 2017

June 5, 2017

Cambridge, Mass., June 5, 2017 - Mersana Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform with DolaLock payload technology, today presented a Trials in Progress abstract at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL that confirmed the continued advancement of its Phase 1 clinical trial for XMT-1522.

The poster presentation is titled: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2. The poster was presented by Howard A. Burris, M.D., President, Clinical Operations & Chief Medical Officer of the Sarah Cannon Research Institute in Nashville, TN. The abstract included authors from Sarah Cannon, Mary Crowley Cancer Research Institute (Dallas, TX), Massachusetts General Hospital (Boston, MA), Moffitt Cancer Center (Tampa, FL), and Mersana Therapeutics.

In October, 2016, U.S. Food and Drug Administration (FDA) cleared Mersana’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for XMT-1522, which is the company’s first pipeline product, and could define a new class of HER2-targeted therapies. 

“The clinical experience with XMT-1522 to date has been consistent with the promising preclinical data,” said Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer, Mersana Therapeutics. “We look forward to providing interim Phase 1 results for XMT-1522 at a scientific conference later in 2017 as well as beginning clinical trials in Q1 2018 with XMT-1536, our second Dolaflexin ADC. We anticipate that the Phase 1 data for these two assets will establish the potential of the Dolaflexin ADC platform to generate products that bring meaningful clinical benefit to patients.”

For more information on the Phase 1 clinical trial of XMT-1522 please visit

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients.  Our lead product candidate, XMT1522, is in Phase I clinical trials. We expect that our second product candidate, XMT1536, will be entering clinical trials in early 2018.  In addition, our partners are advancing their pipeline of ADCs using our platform.

Media Contact
Paul Kidwell